David Roofeh

University of Michigan–Ann Arbor

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Dinesh Khanna

University of Michigan–Ann Arbor

Alain Lescoat

Institut de Recherche en Santé, Environnement et Travail

Sanjiv Kumra

Central University of Punjab

Suiyuan Huang

University of Michigan–Ann Arbor

Kelly Cervellione

Jamaica Hospital

Christopher P. Denton

University College London

Yannick Allanore

Délégation Paris 5

Whitney Townsend

A. Alfred Taubman Health Care Center

Vivek Nagaraja

Michigan Medicine

John D Pauling

North Bristol NHS Trust

Cooperative Institutions

Klinik und Poliklinik für Kinder- und Jugendpsychiatrie

University of Michigan–Ann Arbor

Harvard University

Klinik und Poliklinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters

Philipps University of Marburg

Zucker Hillside Hospital

Center for Rheumatology

Universitätsklinik für Kinder und Jugendpsychiatrie

University of Cologne

American Academy of Child and Adolescent Psychiatry

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Treatment of systemic sclerosis associated ILD: Lessons from clinical trials.

PubMed (2020)

David Roofeh Oliver Distler Yannick Allanore Christopher P. Denton Dinesh Khanna

Systemic therapy

Scleroderma (fungus)

Progressive systemic sclerosis

Source

Cite

Citations (7)

Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort

Arthritis Research & Therapy (2021)

Sara Jaafar Alain Lescoat Suiyuan Huang Jessica Gordon Monique Hinchcliff

Early diffuse cutaneous systemic sclerosis (dcSSc) has the highest case fatality among rheumatic diseases. We report baseline characteristics, current immunosuppressive therapies, progression of skin and internal organ involvement, and mortality in a multicenter prospective cohort from the United States (US) of America.

Case fatality rate

10.1186/s13075-021-02548-1

Cite

Citations (46)

Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol

BMJ Open (2021)

Alain Lescoat David Roofeh Whitney Townsend Michael Hughes Robert D Sandler

Introduction Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of systemic sclerosis. Despite this, lcSSc is not the major focus of clinical studies. The lack of interventional studies in lcSSc is due, in part, to a paucity of relevant outcome measures to effectively evaluate this subset. A combined response index dedicated to lcSSc would facilitate development of well-designed trials and approval of new drugs. The objective of this scoping review is to perform a broad and comprehensive identification of the outcome measures (core set items) within relevant domains, which have been used so far to assess lcSSc. Methods and analysis The planned scoping review will be based on the approach proposed by Arksey et al and further developed by Levac et al . Development and reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses—Extension for Scoping Reviews checklist and guidelines. The development of the search strategy was guided by the concepts of domains and outcomes based on the Outcome Measures in Rheumatology approach and by the different names and definitions of SSc, with a specific emphasis on their occurrence in clinical trial studies. Two databases will be searched: MEDLINE and Embase. Studies in English, published from the year 1988 onwards, will be included, since 1988 corresponds to the publication of LeRoy’s first consensus definition of lcSSc. Data will be extracted and analysed using a standardised charting tool. Ethics and dissemination No ethical approval is required for this study. The results will be submitted to an international peer-reviewed journal and scientific conferences, informing the discussion on which items should be included in a combined response index dedicated to lcSSc (the CRISTAL project: Combined Response Index for Scleroderma Trial Assessing lcSSc).

Grey Literature

10.1136/bmjopen-2020-044765

Cite

Citations (6)

Treatment for systemic sclerosis-associated interstitial lung disease

Current Opinion in Rheumatology (2021)

David Roofeh Alain Lescoat Dinesh Khanna

Purpose of review This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios. Recent findings Broad treatment categories include traditional cytotoxic therapies, biologic disease-modifying rheumatic drugs, antifibrotic agents, autologous hematopoietic stem cell transplant, and lung transplantation. The optimal use of each option varies depending on SSc-ILD severity, progression, and comorbidities of individual patients. A high-quality randomized controlled trial demonstrated nintedanib's ability to retard decline of lung function in patients with limited and diffuse cutaneous disease, with established ILD. Tocilizumab, recently approved by the FDA, provides a unique intervention in those with early SSc associated with ILD with elevated acute-phase reactants: two well designed trials showed lung function preservation in phase 2 and phase 3 trials. Summary Stratifying patients based on key SSc-ILD characteristics (e.g. severity, risk of progression, comorbid disease presentation) may provide a useful guide for practitioners treating SSc-ILD.

Nintedanib

Tocilizumab

Scleroderma (fungus)

10.1097/bor.0000000000000795

Cite

Citations (36)

A pilot trial of integrating the Patient-Reported Outcome Measurement Information System (PROMIS®) into rheumatology care

Clinical and Experimental Rheumatology (2024)

Rosemary Gedert Danielle N. Ochocki Neda Kortam Suiyuan Huang Vivek Nagaraja

Patient-reported outcome

10.55563/clinexprheumatol/fp914f

Cite

Citations (0)

Medial temporal structures and memory functions in adolescents with heavy cannabis use

Journal of Psychiatric Research (2011)

Manzar Ashtari Brian Avants Laura Cyckowski Kelly Cervellione David Roofeh

Effects of cannabis

Cannabis Dependence

10.1016/j.jpsychires.2011.01.004

Cite

Citations (229)

Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials

Expert Opinion on Emerging Drugs (2020)

David Roofeh Alain Lescoat Dinesh Khanna

Introduction Systemic sclerosis (SSc) has the highest case-specific mortality of all connective tissue diseases. Its underlying disease mechanism affects several organs and remains incompletely understood. Ongoing work clarifying its etiopathogenesis is helping to develop targeted therapy.Areas covered Several clinical trials have evaluated the safety and efficacy of agents targeting different mechanisms of this disease. This review article reviews those mechanisms and surveys four key recent phase II or III clinical trials that are contributing to the landscape of SSc therapy. The reported trials primarily focus on patients with systemic sclerosis in the early phase of disease.Expert opinion Traditional therapies for SSc center on immunosuppressive and cytotoxic agents. A new cadre of therapies is borne from improved understandings of SSc pathobiology and target the inflammatory-fibrotic pathways. Scleroderma trials have entered the initial phase of personalized medicine, recognizing molecular subsets that will improve upon cohort enrichment and maximize the measurable benefit of future therapies.

Scleroderma (fungus)

Systemic therapy

10.1080/14728214.2020.1836156

Cite

Citations (11)

Hematological Adverse Events in Clozapine-Treated Children and Adolescents

Journal of the American Academy of Child & Adolescent Psychiatry (2005)

Ginny Gerbino-Rosen David Roofeh D. Andrew Tompkins Doug Feryo Laurie Nusser

Absolute neutrophil count

Leukopenia

Cumulative incidence

10.1097/01.chi.0000171904.23947.54